Breaking Finance News

Relypsa Inc (NASDAQ:RLYP) has been downgraded from Buy to Hold in a statement by Stifel Nicolaus earlier today.

Only yesterday Relypsa Inc (NASDAQ:RLYP) traded 0.00% even at $31.96. RLYP’s 50-day moving average is $30.31 and its 200-day average is $20.28. The last stock close is up 57.77% relative to the 200-day average, compared to the S&P 500 Index which has fallen -0.01% over the same period. Trade volume was was down over the average, with 0 shares of RLYP changing hands under the typical 3,362,590 shares..

Stifel Nicolaus has downgraded Relypsa Inc(NASDAQ:RLYP) from Buy to Hold in a report released 8/22/2016.

Recent Performance Graphic:

Relypsa Inc (NASDAQ:RLYP)

In addition to Stifel Nicolaus reporting it’s stock price target, a total of 12 equity analysts have issued a report on the company. The one year target is $32.00 with eight analysts rating the company a strong buy, three firms rating the stock a buy, one firm rating the stock a hold, two brokerages rating the stock to underperform, and finally 0 analysts rating the stock as sell.

With a market capitalization of $0.0, Relypsa Inc has a 52 week low of $10.26 and a 52 week high of $32.12 with a PE ratio of 0.

About Relypsa Inc (NASDAQ:RLYP)

Relypsa, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia. Hyperkalemia is a life threatening condition defined as abnormally elevated levels of potassium in the blood. Veltassa is a non-absorbed, potassium binding polymer. The active ingredient in Veltassa is a cross-linked polymeric bead that includes calcium as a counterion. Veltassa is a dry powder that is combined with small amounts of water prior to administration. Veltassa is packaged in single-use packets containing approximately 8.4 grams, 16.8 grams or 25.2 grams patiromer, and with a recommended starting dose of approximately 8.4 grams patiromer once daily.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *